. Author manuscript; available in PMC: 2017 Feb 1.

Published in final edited form as: Cancer Immunol Res. 2015 Nov 20;4(2):157–164. doi: 10.1158/2326-6066.CIR-15-0165

Table 2.

Cox univariate analysis of OvCa patient survival

Patients	Variable	Hazard Ratio	95% CI	P-value (Wald)
Stages I/II and III	CA125	4.651	(1.053, 20.539)	0.043
	Anti-CA125	0.758	(0.279, 2.055)	0.586
	Anti-DISGTNTSRA	0.551	(0.199, 1.521)	0.250
Stage III	CA125	2.851	(0.642, 12.657)	0.168
	Anti-CA125	0.678	(0.241, 1.910)	0.462
	Anti-DISGTNTSRA	0.620	(0.210, 1.831)	0.387
Stages I/II and III	CA125 normal/anti-CA125 positive	0.357	(0.132, 0.965)	0.042
Stage III	CA125 normal/anti-CA125 positive	0.461	(0.163, 1.302)	0.144